[1] Kathman SJ, et, al. Population pharmacokinetic-pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers. CPT Pharmacometrics Syst Pharmacol. 2022 Jan;11(1):68-81. DOI:
10.1002/psp4.12734[2] Almquist J, et, al. Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling. CPT Pharmacometrics Syst Pharmacol. 2016 Jun;5(6):313-23. DOI:
10.1002/psp4.12089